Guangzhou LBP Medicine Science & Technology , Ltd. EBIT

The latest EBIT for 688393.SS is $-38M as of June 2026. That compares with $-16M in the prior-year period — down 134.6% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Guangzhou LBP Medicine Science & Technology , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 688393.SS's EBIT moved from $-16M to $-38M — a 134.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Guangzhou LBP Medicine Science & Technology , Ltd.'s operating scale or balance-sheet position.

Against its sector companies, 688393.SS currently prints $-38M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Guangzhou LBP Medicine Science & Technology , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $-38M for 688393.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting 688393.SS's EBIT ($-38M), review year-over-year change from $-16M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.